SCHEMBL15701136

SCHEMBL15701136

CC(NC(=O)Cc1ccc(NC(=O)c2cscn2)cc1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 8/20 0.53
CYP2C8 P10632 4/20 0.53
KMT2A Q03164 3/20 0.48
CYP3A4 P08684 2/20 0.46
GPR139 Q6DWJ6 1/20 0.44
CYP2D6 P10635 2/20 0.44
MEN1 O00255 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP2C19 P33261 1/20 0.42
CA2 P00918 1/20 0.41
MAPT P10636 2/20 0.41
CBLB Q13191 1/20 0.41
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17147291 0.84 CYP2C9 (0.55) CYP2C9CYP2C8KMT2ACYP3A4CYP2D6
SCHEMBL17147290 0.84 CYP2C9 (0.55) CYP2C9CYP2C8KMT2ACYP3A4CYP2D6
SCHEMBL15701042 0.84 CYP2C9 (0.55) CYP2C9CYP2C8KMT2ACYP3A4CYP2D6
SCHEMBL15701088 0.82 CYP3A4 (0.52) CYP2C9KMT2ACYP3A4CYP2D6MEN1
SCHEMBL15701089 0.81 CNR1 (0.53) CYP2C9CYP2C8KMT2ACYP3A4CYP2D6
SCHEMBL15701265 0.80 PSEN1 (0.50) CYP2C9KMT2ACYP3A4CYP2D6MEN1
SCHEMBL7075380 0.79 CYP2C9 (0.49) CYP2C9CYP2C8KMT2ACYP3A4CYP2D6
SCHEMBL15701097 0.78 RIOK2 (0.56) CYP2C9KMT2ACYP3A4CYP2D6MEN1
SCHEMBL7908147 0.78 CYP2C9 (0.47) CYP2C9CYP2C8KMT2ACYP3A4CYP2D6
SCHEMBL7743967 0.78 CYP2C9 (0.47) CYP2C9CYP2C8KMT2ACYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2914592-B1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INT (DE) 2017-10-11 EP disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
WO-2014070979-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS CDKN1A, CCNA1, IFNAR1 CYP2C9 2373/4885CYP2C8 2028/4885KMT2A 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.